A study of Sorafenib and Bavituximab plus Stereotactic Body Radiation Therapy (SBRT) for unresectable hepatitis C associated hepatocellular carcinoma.
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Bavituximab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 07 Sep 2017 According to a Peregrine Pharmaceuticals media release, National Comprehensive Cancer Network (NCCN) is responsible for oversight and monitoring of this and other two clinical studies (CTP700276383 and CTP276389) through the research grant.
- 28 Mar 2017 Status changed from not yet recruiting to recruiting.
- 25 Jan 2017 Planned initiation date changed from 1 Feb 2017 to 30 Apr 2017.